Session Information
Date: Thursday, June 23, 2016
Session Title: Other
Session Time: 12:00pm-1:30pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: To study effect of dopamine and L-3,4 – dihydroxyphenylalanine in treatment of experimental parkinsonism.
Background: Prospects of treatment of Parkinson’s disease are also closely connected with the further conduct of clinical trials of new drugs, in spite of achievements, development of new approaches to Parkinson’s disease replacement therapy aimed at increasing its effectiveness remains valid.
Methods: Experiments were performed in 5-month-old male mice line C57BL / 6 mice weighing 23-25 g PS simulated by intraperitoneal (i / p) MPTP administration in the dose of 20 mg / kg two times a day at intervals of 12 hours for 7 days, and 21 days (Kryzhanozsky et al., 1995). Animals were decapitated on the 7th day after 1 h after single administration and after prolonged administration of drugs – 22 th day.
Results: Introduction of MPTP during 7 days – accompanied by a decline inPS, DOFUK and HVA in the striatum by 80%, 70% and 60%, respectively. Contents of dopamine in MPTP administration on day 21 decreased to 90% of level konrol group. A single injection of L-DOPA in the MOT, unlike 10-fold higher dose of free L-DOPA. did not increase the absolute content PS DOFUK and GVK in striatum of mice with MPTP-induced PS, but similar free L-DOPA (50 mg / kg) in 2-fold increase in metabolic rate PS to DOFUK (DOFUK / TA) and GVA. Free L-DOPA in a dose equivalent to the liposome and "empty" MOL after a single administration does not change the neurochemical communication parameters PS.
Conclusions: Thus, the results should generally be regarded as a neurochemical confirm the effectiveness of anti-Parkinsonian extremely small doses of L-DOPA and DA concluded in MOL. Moreover, from the data obtained that the dose L-DOPA, necessary for partial compensation deficit DA and its metabolites in MPTP-induced PS in mice can be reduced by 10 times, thanks to the encapsulation of the drug in MOL.
To cite this abstract in AMA style:
M.U. Kulmanova. Effect of dopamine and L-3,4 – dihydroxyphenylalanine in treatment of experimental parkinsonism [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/effect-of-dopamine-and-l-34-dihydroxyphenylalanine-in-treatment-of-experimental-parkinsonism/. Accessed May 14, 2025.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/effect-of-dopamine-and-l-34-dihydroxyphenylalanine-in-treatment-of-experimental-parkinsonism/